| |
| |
|
| Insider
Information: |
Lewis Joseph |
| Relationship: |
10% Owner |
| City: |
|
| State: |
C5 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
12 |
|
| Direct
Shares |
86,185,130 |
|
|
Indirect Shares
|
72,160,714 |
|
|
| Direct
Value |
$13,314,563,542 |
|
|
|
Indirect Value
|
$3,987,125 |
|
|
| Total
Shares |
158,345,844 |
|
|
| Total
Value |
$13,318,550,667 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
8
|
7
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
8
|
7
|
| |
|
|
|
Gain/Loss Ratio : |
-8.0
|
-7.0
|
| Percentage
Gain/Loss : |
 -77.8%
|
-196.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Baycorp Holdings Ltd |
MWH |
10% Owner |
2005-11-10 |
524,310 |
2005-11-10 |
0 |
Premium* |
|
|
Somaxon Pharmaceuticals, Inc. |
SOMX |
Member of 13(d) group |
2009-08-26 |
876,489 |
2009-07-27 |
0 |
Premium* |
|
|
Aradigm Corp |
ARDM |
10% Owner |
2013-05-20 |
57,517,914 |
2013-05-20 |
51,512,735 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
10% Owner |
2021-03-10 |
3,135,966 |
|
0 |
Premium* |
|
|
Sophiris Bio Inc. |
SPHS |
10% Owner |
2013-08-16 |
246,153 |
|
0 |
Premium* |
|
|
Odonate Therapeutics Inc |
ODT |
10% Owner |
2021-11-19 |
4,607,086 |
2017-12-06 |
0 |
Premium* |
|
|
Esperion Therapeutics, Inc. |
ESPR |
10% Owner |
2018-11-05 |
1,101,250 |
2018-11-02 |
0 |
Premium* |
|
|
Inseego Corporation |
INSG |
|
2023-09-29 |
356,903 |
2023-09-29 |
20,647,979 |
Premium* |
|
|
Rain Therapeutics Inc. |
RAIN |
10% Owner |
2021-04-27 |
1,175,000 |
2021-04-23 |
0 |
Premium* |
|
|
Tyra Biosciences, Inc. |
TYRA |
10% Owner |
2021-12-17 |
6,448,359 |
2021-12-17 |
0 |
Premium* |
|
|
Tango Therapeutics Ord Shs |
TNGX |
10% Owner |
2022-10-06 |
7,053,642 |
|
0 |
Premium* |
|
|
Iteos Therapeutics, Inc. |
ITOS |
10% Owner |
2022-03-17 |
3,142,058 |
2022-03-17 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
– – • |
2020-10-28 |
4 |
S |
$203.35 |
$61,027,546 |
D/D |
(295,436) |
2,840,530 |
0 |
% |
|
| INSG |
Inseego Corporation |
10% Owner |
– – • |
2018-12-19 |
4 |
B |
$3.00 |
$29,258,187 |
D/D |
9,752,729 |
18,799,229 |
2.45 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
– – • |
2020-10-29 |
4 |
S |
$203.32 |
$22,306,891 |
D/D |
(104,564) |
3,031,402 |
0 |
% |
|
| ITOS |
Iteos Therapeutics, Inc. |
10% Owner |
– – • |
2022-03-17 |
4 |
S |
$35.25 |
$20,275,835 |
D/D |
(575,201) |
3,142,058 |
0 |
- |
|
| ODT |
Odonate Therapeutics Inc |
10% Owner |
– – • |
2020-08-28 |
4 |
B |
$14.25 |
$20,000,003 |
D/D |
1,403,509 |
4,766,886 |
2.45 |
% |
|
| RAIN |
Rain Therapeutics Inc. |
10% Owner |
– – • |
2021-04-27 |
4 |
B |
$17.00 |
$17,425,000 |
D/D |
1,025,000 |
1,175,000 |
2.45 |
- |
|
| ODT |
Odonate Therapeutics Inc |
10% Owner |
– – • |
2017-12-06 |
4 |
B |
$24.00 |
$9,999,984 |
D/D |
416,666 |
2,726,938 |
2.45 |
- |
|
| SPHS |
Sophiris Bio Inc. |
10% Owner |
– – • |
2013-08-16 |
4 |
B |
$5.00 |
$8,000,000 |
D/D |
1,600,000 |
246,153 |
2.45 |
- |
|
| INSG |
Inseego Corporation |
10% Owner |
– – • |
2019-03-28 |
4 |
OE |
$2.52 |
$7,979,013 |
D/D |
3,166,275 |
21,965,504 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
– – • |
2018-06-07 |
4 |
B |
$38.85 |
$7,499,993 |
D/D |
193,050 |
1,565,560 |
2.45 |
- |
|
| MWH |
Baycorp Holdings Ltd |
10% Owner |
– – • |
2005-11-10 |
4 |
B |
$14.19 |
$7,085,209 |
D/D |
499,310 |
524,310 |
2.45 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
– – • |
2013-10-24 |
4 |
B |
$17.50 |
$7,000,000 |
D/D |
400,000 |
429,341 |
2.45 |
- |
|
| INSG |
Inseego Corporation |
Director |
– • • |
2019-08-09 |
4 |
A |
$1,000.00 |
$7,000,000 |
D/D |
7,000 |
7,000 |
0 |
- |
|
| ODT |
Odonate Therapeutics Inc |
10% Owner |
– – • |
2020-12-28 |
4 |
B |
$16.90 |
$5,117,048 |
D/D |
300,000 |
5,507,086 |
2.45 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
10% Owner |
– – • |
2018-11-05 |
4 |
S |
$55.21 |
$3,429,843 |
D/D |
(60,000) |
1,101,250 |
0 |
- |
|
| RAIN |
Rain Therapeutics Inc. |
10% Owner |
– – • |
2021-04-23 |
4 |
B |
$15.58 |
$2,423,250 |
D/D |
150,000 |
150,000 |
2.45 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
10% Owner |
– – • |
2021-03-09 |
4 |
S |
$191.00 |
$2,366,252 |
D/D |
(11,971) |
3,135,966 |
0 |
% |
|
| ESPR |
Esperion Therapeutics, In... |
10% Owner |
– – • |
2018-11-02 |
4 |
S |
$54.65 |
$2,208,500 |
D/D |
(40,000) |
1,161,250 |
0 |
- |
|
| ODT |
Odonate Therapeutics Inc |
10% Owner |
– – • |
2020-09-04 |
4 |
B |
$14.89 |
$1,862,739 |
D/D |
125,100 |
4,891,986 |
2.45 |
% |
|
| ODT |
Odonate Therapeutics Inc |
10% Owner |
– – • |
2020-12-30 |
4 |
B |
$17.46 |
$1,746,380 |
D/D |
100,000 |
5,607,086 |
2.45 |
% |
|
| ODT |
Odonate Therapeutics Inc |
10% Owner |
– – • |
2020-09-29 |
4 |
B |
$14.08 |
$1,717,760 |
D/D |
122,000 |
5,207,086 |
2.45 |
% |
|
| TYRA |
Tyra Biosciences, Inc. |
10% Owner |
– – • |
2021-12-17 |
4 |
B |
$13.12 |
$1,640,313 |
D/D |
125,000 |
6,448,359 |
2.45 |
- |
|
| SOMX |
Somaxon Pharmaceuticals, ... |
Member of 13(d) group |
– – – |
2009-07-27 |
4 |
S |
$3.10 |
$1,550,000 |
D/D |
(500,000) |
971,489 |
0 |
- |
|
| ODT |
Odonate Therapeutics Inc |
10% Owner |
– – • |
2018-12-21 |
4 |
B |
$13.46 |
$1,347,015 |
D/D |
100,000 |
2,953,762 |
2.45 |
- |
|
| ODT |
Odonate Therapeutics Inc |
10% Owner |
– – • |
2021-11-17 |
4 |
S |
$2.17 |
$1,299,240 |
D/D |
(600,000) |
5,007,086 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
